Rayence Co Ltd

Rayence's capital structure is characterized by a low debt-to-equity ratio of 0.02, indicating a conservative leverage profile. The company holds significant liquidity with cash and equivalents amounting to KRW 47.5 billion, which is 18.2% of total assets. The current ratio of 14.95 suggests strong short-term liquidity, well above the industry median for medical equipment manufacturers. However, the company's free cash flow is negative at KRW -4.5 billion, driven by capital expenditures of KRW -2.3 billion. Profitability metrics show a challenging operating environment for Rayence. The company reported a net loss of KRW -5.3 billion and an operating loss of KRW -9.2 billion in the latest period. Return on equity (ROE) and return on assets (ROA) are negative at -2.23% and -2.02%, respectively, both significantly below the industry median for medical equipment firms. Gross profit margin stands at 35.7%, which is in line with the industry median, but operating margin is negative at -7.99%, indicating operational inefficiencies. Rayence's revenue is derived from the sale of X-ray detectors and related medical imaging equipment. The company operates in both domestic and international markets, but the input data does not provide specific geographic revenue breakdowns. The product portfolio includes TFT and CMOS detectors, intraoral sensors, and mammography machines. The company's brand names include 1012WCA, 17SCC/SGC, 1215CF, 1501CF, 0712CF, Ez1.0, and 1724CM, 2434CM. The company's growth trajectory is mixed. Revenue in the latest period was KRW 114.7 billion, but the outlook for the current fiscal year is uncertain due to the operating losses. Analysts have set a mean price target of KRW 7,000, which is 15.1% above the current market price of KRW 6,080. However, the lack of strong buy recommendations and the negative operating performance suggest caution in the near term. Risk factors for Rayence include the potential for operational losses to persist, which could pressure liquidity and equity. The company's dilution risk is currently low, with no immediate filing-based flags detected. However, the negative free cash flow and capital expenditures may necessitate future financing, which could lead to dilution. The company's liquidity position is strong, but the negative operating cash flow of KRW -9.2 billion is a concern. Recent events include the latest financial filing, which shows a net loss and operating loss. The company's financial performance has not attracted strong buy recommendations from analysts, with only one buy rating and no strong buy ratings. The mean recommendation is 2.00, indicating a hold or cautious outlook.